<DOC>
	<DOCNO>NCT00574275</DOCNO>
	<brief_summary>The main objective study evaluate effectiveness aflibercept treatment comparison placebo increase overall survival ( OS ) participant metastatic pancreatic cancer , treat gemcitabine . The secondary objective evaluate progression free survival , clinical benefit , overall response , safety immunogenicity aflibercept , two treatment arm ( Arm 1 : Aflibercept Gemcitabine ; Arm 2 : Placebo Gemcitabine ) . The study include interim analysis OS . In accordance study protocol , interim analysis perform purpose futility overwhelm efficacy . On basis interim analysis , Data Monitoring Committee ( DMC ) recommend study terminate futility base predefined boundary rule .</brief_summary>
	<brief_title>Aflibercept Compared Placebo Term Efficacy Patients Treated With Gemcitabine Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>The study include : - A screening visit 21 day prior randomization - Randomization baseline - A Treatment period ( initiate within 3 day randomization ) , include 28-day treatment cycle arm predefined treatment discontinuation criterion meet - A follow-up visit 30 day discontinuation treatment , - A post study treatment follow-up period death study cutoff date . The criterion treatment discontinuation : - Participant ( legal representative ) choose withdraw treatment - The investigator think continuation study would detrimental participant well-being , : - Disease progression - Unacceptable AEs manageable symptomatic therapy , dose delay , dose modification - Intercurrent illness prevent administration study treatment - Noncompliance study protocol - Participant lose follow-up - Unblinding participant 's investigational treatment</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Cytologically histologically confirm evidence epithelial cancer ( adenocarcinoma ) exocrine pancreas Metastatic disease No prior chemotherapy pancreatic disease Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 , 1 2 Adequate renal , liver bone marrow function Less 42 day elapse prior major surgery ( 28 day prior surgery ) time randomization Prior treatment antiVEGF VEGFReceptorinhibitors Uncontrolled hypertension Pregnancy breastfeed Participant reproductive potential ( M/F ) without effective method contraception The information intend contain consideration relevant potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>metastatic pancreatic cancer</keyword>
	<keyword>angiogenesis inhibitor</keyword>
	<keyword>gemcitabine</keyword>
</DOC>